By Elena Vardon

AstraZeneca said the U.S. Food and Drug Administration approved the use of its Imfinzi immunotherapy along with chemotherapy for endometrial cancer.

The British-Swedish pharma giant said Monday that it received approval in the U.S. for the drug--in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy--to be used to treat adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient.

The FDA gave the group the green light based on the results of its DUO-E Phase 3 trial, which showed Imfinzi reduced the risk of disease progression or death by 58% against chemotherapy alone, AstraZeneca said.

Write to Elena Vardon at

(END) Dow Jones Newswires

06-17-24 0229ET